+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
T-Cell & NK-Cell Engaging Bispecific Antibodies Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
T-Cell & NK-Cell Engaging Bispecific Antibodies Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

T-Cell & NK-Cell Engaging Bispecific Antibodies Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6081317
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The rapid evolution of bispecific antibodies that engage T cells and natural killer cells marks a pivotal chapter in immunotherapy. By simultaneously binding a tumor-associated antigen and an immune effector receptor, these constructs harness the body’s intrinsic defenses to target and eliminate malignant cells with unprecedented precision. This approach offers the promise of enhanced cytotoxicity, reduced off-target effects, and adaptable platform engineering. As a result, developers are pushing the boundaries of molecular design, optimizing dual specificity, affinity tuning, and half-life extension to maximize therapeutic windows. Meanwhile, collaborations between biotech innovators, academic centers, and large pharmaceutical players are accelerating pipeline advancement. Against this backdrop, decision-makers must understand the technological milestones, regulatory considerations, and commercial dynamics reshaping the bispecific antibody space. The following executive summary distills these critical insights to inform strategic planning and investment priorities.

Transformative Shifts Redefining Bispecific Antibody Development

Bi- and multispecific formats have disrupted the traditional monoclonal antibody paradigm, giving rise to modular platforms that can be tailored for dual immune engagement. Initially, first-generation bispecifics faced challenges related to stability, manufacturability, and immunogenicity. However, advances in antibody engineering-such as knob-into-hole heterodimerization, Fc silencing, and glycoengineering-have surmounted many of these obstacles. Consequently, next-generation constructs demonstrate improved pharmacokinetics and manufacturability. At the same time, novel payload delivery strategies, including conditional activation and cytokine recruitment, are expanding therapeutic reach beyond oncology into autoimmune and infectious disease arenas. Moreover, the integration of computational modeling and high-throughput screening accelerates candidate selection, allowing developers to rapidly iterate affinities and valencies. This transformative shift underscores the transition from single-target antibodies to multifunctional immunotherapeutics designed for precision targeting and controlled activation.

Evaluating the Cumulative Impact of US Tariffs in 2025 on Supply Chains

New tariff schedules introduced in early 2025 have increased duties on biologic components, recombinant proteins, and critical raw materials imported into the United States. As a result, manufacturers sourcing cell culture media, chromatography resins, and analytical assay kits from international suppliers face elevated production costs. These added expenses strain tight development budgets and may delay scale-up activities. In response, some organizations are reshoring key processes or negotiating long-term supply agreements to hedge against price volatility. Simultaneously, alternative sourcing strategies-such as localizing reagent production and qualifying domestic vendors-are gaining traction. Meanwhile, regulatory agencies are streamlining import inspections for life-science goods to mitigate potential bottlenecks. Overall, the cumulative impact of tariffs in 2025 is reshaping supply-chain resilience and cost management, compelling stakeholders to reassess procurement strategies and operational footprints.

Key Segmentation Insights Shaping Market Dynamics

A granular understanding of disease focus, therapeutic modalities, molecular targets, development stage, end-user landscape, biologic subtype, and application scenario is vital for strategic segmentation. The market is studied across Autoimmune Diseases, Infectious Diseases, and Oncology under therapeutic area, while products are distinguished between bispecific NK-cell engagers and bispecific T-cell engagers in the product type segment. Targeted molecules such as BCMA, CD19, CD20, and CD3 define precision parameters, and tracking between clinical trials and research and development highlights maturity. End-users span clinical research organizations, pharmaceutical companies, and research institutions, each with distinct adoption drivers and budget constraints. Biologics are classified into antibody-drug conjugates and monoclonal antibodies, reflecting payload strategies and structural complexity. Finally, applications range from research use only to therapeutic uses, illustrating the continuum from discovery to clinical deployment. This multidimensional segmentation provides a foundation for targeted portfolio expansion and tailored commercialization tactics.

Regional Insights Highlighting Geographic Drivers and Barriers

Geographic nuances drive differential access, reimbursement frameworks, and R&D investment patterns. The Americas boast robust clinical trial infrastructure, extensive venture funding, and established biologics manufacturing hubs, making the region a primary launchpad and commercialization stronghold. Europe, Middle East & Africa present a heterogeneous regulatory landscape, with the European Union’s centralized agency model coexisting alongside localized approval pathways in Middle Eastern countries and variable reimbursement criteria across Africa. These factors influence market entry sequencing and pricing negotiations. Asia-Pacific, characterized by rapidly expanding biotech ecosystems in China, Japan, and South Korea, combines government-backed innovation programs with cost-effective contract manufacturing. As a result, partnerships with regional biotechs and early regulatory engagement strategies are essential for success. Together, these regional insights guide allocation of resources, alliance formation, and go-to-market planning.

Key Company Profiles Driving Innovation and Competition

Competitive analysis reveals a diverse roster of organizations pursuing bispecific platforms, spanning clinical pioneers to platform specialists. Affimed N.V. and Agenus Inc. are advancing NK-cell engager pipelines, leveraging proprietary Fc engineering and cytokine fusion constructs, respectively. Alphamab Oncology and Harpoon Therapeutics, Inc. focus on novel formats aimed at optimizing tumor penetration and conditional activation. Meanwhile, established players such as Amgen Inc., AstraZeneca PLC, Genentech, Inc., and Regeneron Pharmaceuticals, Inc. integrate bispecific modules into broad immuno-oncology portfolios. Companies like F-star Therapeutics, Inc., Genmab A/S, IGM Biosciences, Inc., and MacroGenics, Inc. are differentiating through unique scaffold technologies and multispecific design. Emerging entities, including Kiniksa Pharmaceuticals, Ltd. and Xencor, Inc., emphasize tunable effector functions and half-life extension. Collectively, these companies define the competitive landscape, driving innovation and shaping partnership opportunities.

Actionable Recommendations to Navigate Emerging Challenges

Industry leaders should adopt a multi-pronged strategy to navigate evolving challenges and capture emerging opportunities. First, investing in modular engineering platforms will accelerate candidate optimization and reduce development timelines. Second, diversifying supply-chain partnerships by qualifying domestic and regional vendors can mitigate tariff-related cost pressures. Third, establishing collaborative consortia with academic institutions and contract research organizations will broaden access to novel targets and accelerate translational research. Fourth, tailoring regulatory engagement-through early dialogue with health authorities-can streamline clinical pathways and anticipate policy changes. Fifth, implementing adaptive commercial models that leverage real-world evidence and value-based contracting will position organizations for favorable reimbursement outcomes. Finally, monitoring competitive moves through strategic intelligence and forging co-development alliances will enable rapid response to market shifts. By executing these recommendations, stakeholders can strengthen their competitive posture and deliver next-generation immunotherapies more efficiently.

Conclusion: Positioning for Long-Term Success in a Competitive Arena

The bispecific antibody arena continues to evolve at a breakneck pace, driven by technological breakthroughs, strategic collaborations, and shifting policy landscapes. Stakeholders who harness modular design approaches, reinforce supply-chain resilience, and engage in proactive regulatory planning will lead the next wave of clinical successes. Moreover, nuanced segmentation and regional strategies will inform market prioritization, while close collaboration with key platform innovators and research organizations will fuel differentiation. Ultimately, organizations that combine scientific rigor with commercial agility will unlock the full potential of T-cell and NK-cell engaging bispecifics, transforming patient outcomes across oncology, autoimmune, and infectious disease settings.

Market Segmentation & Coverage

This research report categorizes the T-Cell & NK-Cell Engaging Bispecific Antibodies Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Autoimmune Diseases
  • Infectious Diseases
  • Oncology
  • Bispecific NK-Cell Engagers
  • Bispecific T-Cell Engagers
  • BCMA
  • CD19
  • CD20
  • CD3
  • Clinical Trials
  • Research and Development
  • Clinical Research Organizations
  • Pharmaceutical Companies
  • Research Institutions
  • Antibody-Drug Conjugates
  • Monoclonal Antibodies
  • Research Use Only
  • Therapeutic Uses

This research report categorizes the T-Cell & NK-Cell Engaging Bispecific Antibodies Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the T-Cell & NK-Cell Engaging Bispecific Antibodies Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Affimed N.V.
  • Agenus Inc.
  • Alphamab Oncology
  • Amgen Inc.
  • AstraZeneca PLC
  • F-star Therapeutics, Inc.
  • Genentech, Inc.
  • Genmab A/S
  • Harpoon Therapeutics, Inc.
  • IGM Biosciences, Inc.
  • Kiniksa Pharmaceuticals, Ltd.
  • MacroGenics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Xencor, Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. T-Cell & NK-Cell Engaging Bispecific Antibodies Market, by Therapeutic Area
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Infectious Diseases
8.4. Oncology
9. T-Cell & NK-Cell Engaging Bispecific Antibodies Market, by Product Type
9.1. Introduction
9.2. Bispecific NK-Cell Engagers
9.3. Bispecific T-Cell Engagers
10. T-Cell & NK-Cell Engaging Bispecific Antibodies Market, by Targeted Molecule
10.1. Introduction
10.2. BCMA
10.3. CD19
10.4. CD20
10.5. CD3
11. T-Cell & NK-Cell Engaging Bispecific Antibodies Market, by Development Phase
11.1. Introduction
11.2. Clinical Trials
11.3. Research and Development
12. T-Cell & NK-Cell Engaging Bispecific Antibodies Market, by End-User
12.1. Introduction
12.2. Clinical Research Organizations
12.3. Pharmaceutical Companies
12.4. Research Institutions
13. T-Cell & NK-Cell Engaging Bispecific Antibodies Market, by Biologics
13.1. Introduction
13.2. Antibody-Drug Conjugates
13.3. Monoclonal Antibodies
14. T-Cell & NK-Cell Engaging Bispecific Antibodies Market, by Applications
14.1. Introduction
14.2. Research Use Only
14.3. Therapeutic Uses
15. Americas T-Cell & NK-Cell Engaging Bispecific Antibodies Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Affimed N.V.
18.3.2. Agenus Inc.
18.3.3. Alphamab Oncology
18.3.4. Amgen Inc.
18.3.5. AstraZeneca PLC
18.3.6. F-star Therapeutics, Inc.
18.3.7. Genentech, Inc.
18.3.8. Genmab A/S
18.3.9. Harpoon Therapeutics, Inc.
18.3.10. IGM Biosciences, Inc.
18.3.11. Kiniksa Pharmaceuticals, Ltd.
18.3.12. MacroGenics, Inc.
18.3.13. Regeneron Pharmaceuticals, Inc.
18.3.14. Xencor, Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET MULTI-CURRENCY
FIGURE 2. T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET MULTI-LANGUAGE
FIGURE 3. T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 8. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BISPECIFIC NK-CELL ENGAGERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BISPECIFIC T-CELL ENGAGERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BCMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY CD19, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY CD20, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY CD3, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY RESEARCH USE ONLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC USES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 53. CANADA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 54. CANADA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 55. CANADA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 56. CANADA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 57. CANADA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. CANADA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 59. CANADA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 60. MEXICO T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 61. MEXICO T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 64. MEXICO T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. MEXICO T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 66. MEXICO T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. AUSTRALIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 89. AUSTRALIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 90. CHINA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 91. CHINA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. CHINA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 93. CHINA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 94. CHINA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. CHINA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 96. CHINA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 97. INDIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 98. INDIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 99. INDIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 100. INDIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 101. INDIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. INDIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 103. INDIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 104. INDONESIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 105. INDONESIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 106. INDONESIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 107. INDONESIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 108. INDONESIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. INDONESIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 110. INDONESIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 111. JAPAN T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 112. JAPAN T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 113. JAPAN T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 114. JAPAN T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 115. JAPAN T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. JAPAN T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 117. JAPAN T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 118. MALAYSIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 119. MALAYSIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 120. MALAYSIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 121. MALAYSIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 122. MALAYSIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. MALAYSIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 124. MALAYSIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 125. PHILIPPINES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 126. PHILIPPINES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 127. PHILIPPINES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 128. PHILIPPINES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 129. PHILIPPINES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. PHILIPPINES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 131. PHILIPPINES T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 132. SINGAPORE T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 133. SINGAPORE T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. SINGAPORE T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 135. SINGAPORE T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 136. SINGAPORE T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. SINGAPORE T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 138. SINGAPORE T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 139. SOUTH KOREA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 140. SOUTH KOREA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. SOUTH KOREA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 142. SOUTH KOREA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 143. SOUTH KOREA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. SOUTH KOREA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 145. SOUTH KOREA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 146. TAIWAN T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 147. TAIWAN T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 148. TAIWAN T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 149. TAIWAN T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 150. TAIWAN T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. TAIWAN T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 152. TAIWAN T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 153. THAILAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 154. THAILAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 155. THAILAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 156. THAILAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 157. THAILAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. THAILAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 159. THAILAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 160. VIETNAM T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 161. VIETNAM T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. VIETNAM T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 163. VIETNAM T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 164. VIETNAM T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. VIETNAM T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 166. VIETNAM T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 175. DENMARK T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 176. DENMARK T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 177. DENMARK T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 178. DENMARK T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 179. DENMARK T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. DENMARK T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 181. DENMARK T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 182. EGYPT T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 183. EGYPT T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 184. EGYPT T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 185. EGYPT T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 186. EGYPT T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. EGYPT T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 188. EGYPT T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 189. FINLAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 190. FINLAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 191. FINLAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 192. FINLAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 193. FINLAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. FINLAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 195. FINLAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 196. FRANCE T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 197. FRANCE T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. FRANCE T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 199. FRANCE T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 200. FRANCE T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. FRANCE T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 202. FRANCE T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 203. GERMANY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 204. GERMANY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 205. GERMANY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 206. GERMANY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 207. GERMANY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 208. GERMANY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 209. GERMANY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 215. ISRAEL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 216. ISRAEL T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 217. ITALY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 218. ITALY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. ITALY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 220. ITALY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 221. ITALY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 222. ITALY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 223. ITALY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 238. NORWAY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 239. NORWAY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 240. NORWAY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 241. NORWAY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 242. NORWAY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 243. NORWAY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 244. NORWAY T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 245. POLAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 246. POLAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 247. POLAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 248. POLAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 249. POLAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 250. POLAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 251. POLAND T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 252. QATAR T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 253. QATAR T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 254. QATAR T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 255. QATAR T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 256. QATAR T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 257. QATAR T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 258. QATAR T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY TARGETED MOLECULE, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA T-CELL & NK-CELL ENGAGING BIS

Companies Mentioned

  • Affimed N.V.
  • Agenus Inc.
  • Alphamab Oncology
  • Amgen Inc.
  • AstraZeneca PLC
  • F-star Therapeutics, Inc.
  • Genentech, Inc.
  • Genmab A/S
  • Harpoon Therapeutics, Inc.
  • IGM Biosciences, Inc.
  • Kiniksa Pharmaceuticals, Ltd.
  • MacroGenics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Xencor, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Bispecific Antibodies - Global Strategic Business Report - Product Image

Bispecific Antibodies - Global Strategic Business Report

  • Report
  • 104 Pages
  • Global
From
Targeted Therapy Drugs for Melanoma Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Targeted Therapy Drugs for Melanoma Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global, United States Global, United States
From
Natural Killer Cell Therapeutics Market by Therapeutics, Approaches, Application, End User - Global Forecast 2025-2030 - Product Image

Natural Killer Cell Therapeutics Market by Therapeutics, Approaches, Application, End User - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review - Product Image

Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review

  • Report
  • Global
From
Bispecific Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Bispecific Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.